Q2 2025 Pharma Mar SA Earnings Call Transcript
Key Points
- Total revenues grew by 18% compared to the same period last year, indicating strong financial performance.
- The oncology segment significantly contributed to sales and royalty income, demonstrating the ability to generate cash from its own activities.
- R&D investment totaled over €47 million, supporting ongoing clinical development programs.
- Profitability improved with EBITDA reaching €25 million and net profit rising to €19.4 million, more than five times the result of the first half of 2024.
- The marketing authorization application for a new treatment in small cell lung cancer was filed with the EMA, indicating progress in product development.
- Royalty income remained flat due to increased competition in the US and less favorable dollar-euro exchange rates.
- The company decided to withdraw a marketing authorization application for a treatment in multiple myeloma due to changes in clinical practice and available therapies.
- Operating expenses included adjustments due to overestimation of royalties in the first quarter.
- Capital expenditure was significantly reduced, which may impact future growth opportunities.
- Increased competition from other pharmaceutical companies, such as Amgen and Daiichi, poses a challenge in the oncology market.
Hello everyone and welcome to the Farm on my first half 2025 results call. My name is Emily, and I'll be coordinating the call today. I will now hand over to Jose Luis Moreno, Vice President, head of capital markets and investor relations. Please go ahead.
Thank you, Emily, and good morning to everyone.
Thank you for joining today's Faramar endings conference call for the financial results for the first half of 25.
On the call with me today are Maria Luisa francia, Chief Financial Officer, Luis Mora, managing director of Pharmamar, and Pascal Besman, senior Vice President of strategic Development.
Following our prepared remarks today, we will open the line for questions.
I'd like to remind you that today's conference call might include forward-looking statements regarding future events or the future financial and operating performance of a company.
Such forward-looking statements are only predictions
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
